BIOMAT Database Logo BIOMAT Database Logo

[Clinical evaluation of mepartricin in benign prostatic hypertrophy]. 1988

P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli

UI MeSH Term Description Entries
D008297 Male Males
D008613 Mepartricin Polyene macrolide antibiotic with unknown composition. It is obtained from Streptomyces aureofaciens. It is used as an antifungal agent, an antiprotozoal agent, and in the treatment of BENIGN PROSTATIC HYPERTROPHY. Methylpartricin,Mepartricin A,Mepartricin B,Methyl Partricin,SPA-S 160,Tricandil,SPA S 160,SPAS 160
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011090 Polyenes Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES. Cumulenes
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Evaluation of the objective efficacy of mepartricin in benign prostatic hypertrophy].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Mepartricin as medical treatment of benign prostatic hypertrophy].
January 1993, Journal d'urologie,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Use of mepartricin in the treatment of benign prostatic hypertrophy. Evaluation of clinical and functional parameters].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Treatment of benign prostatic hypertrophy using mepartricin at high dosage].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Therapeutic usefulness of mepartricin in benign prostatic hypertrophy: 2 years' experience. Preliminary note on the effect of mepartricin on certain possible etiopathogenic factors in benign prostatic hypertrophy].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Clinical and echographic evaluation of a group of 40 patients suffering from benign prostatic hypertrophy treated with mepartricin].
January 1988, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Double-blind evaluation of mepartricin 150.000 U (40 mg) compared with placebo in benign prostatic hypertrophy].
December 1996, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Clinical evaluation of Cernilton in benign prostatic hypertrophy].
January 1986, Hinyokika kiyo. Acta urologica Japonica,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Role of mepartricin in patients with benign prostatic hypertrophy. Study of 24 patients].
January 1987, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
P Giannotti, and P Murzi, and A Marconi, and D Pistolesi, and G Morelli
[Mepartricin in prostatic hypertrophy. Results in 20 cases].
January 1986, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
Copied contents to your clipboard!